Certara Inc

Отворен

СекторЗдравеопазване

6.8 -2.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.77

Максимум

6.99

Ключови измерители

By Trading Economics

Приходи

-2.9M

-8.8M

Продажби

3.3M

107M

P/E

Средно за сектора

100.714

60.149

EPS

-0.06

Марж на печалбата

-8.196

Служители

1,515

EBITDA

-16M

16M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+12.41% upside

Дивиденти

By Acuity

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

258M

1.1B

Предишно отваряне

9.52

Предишно затваряне

6.8

Настроения в новините

By Acuity

19%

81%

32 / 340 Класиране в Healthcare

Certara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.07.2026 г., 19:31 ч. UTC

News

Certara Inc partners with NVIDIA to enhance its AI biosimulation platform. Shares are higher, reflecting positive market sentiment around the collaboration.

Сравнение с други в отрасъла

Ценова промяна

Certara Inc Прогноза

Ценова цел

By TipRanks

12.41% нагоре

12-месечна прогноза

Среден 7.79 USD  12.41%

Висок 10 USD

Нисък 6 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Certara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

3

Купи

6

Задържане

0

Продай

Настроение

By Acuity

32 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat